Cambrex competitors

Cambrex Competitors include Lonza, Assertio Therapeutics, Aradigm and Albany Molecular Research.
Add company...
Cambrex
Cambrex
Cambrex is an innovative life sciences company with a refreshingly human approach to the way we do business.
Lonza
Lonza
Lonza supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries.
Assertio Therapeutics
Assertio Therapeutics
Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.
Aradigm
Aradigm
Aradigm is a pharmaceutical company focused on the development of drugs for the treatment of severe respiratory diseases.
Albany Molecular Research
Albany Molecular Research
Albany Molecular Research is a pharmaceutical services organization offering Discovery/Development solutions, and Drug Product and API Manufacturing.
Founding Date
Founding Date
1981
Founding Date
1897
Founding Date
1995
Founding Date
1991
Founding Date
1991
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
East Rutherford, US HQ
Locations
Basel, CH HQ
Mt Waverley, AU
Verviers, BE
São Paulo, BR
Suzhou, CN
San José, CR
Kouřim, CZ
see more
Locations
Newark, US HQ
Locations
Hayward, US HQ
Locations
Albany, US HQ
Employees
Employees
1,228
Employees
14,618
Employees
43411% decrease
Employees
23
Employees
N/A
Valuation ($)
Valuation ($)
1.4 b
Valuation ($)
16.4 b
Valuation ($)
259 m
Valuation ($)
7.3 m
Valuation ($)
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
4.9 k
Twitter followers
N/A
Twitter followers
16
Twitter followers
1.1 k

Financial

Revenue (est.)
Revenue (est.)
$523.9m (FY, 2017)
Revenue (est.)
CHF5.1b (FY, 2017)
Revenue (est.)
$380.7m (FY, 2017)
Revenue (est.)
$14.5m (FY, 2017)
Revenue (est.)
$570.5m (FY, 2016)
Cost of goods
Cost of goods
$304.4m (FY, 2017)
Cost of goods
CHF3.3b (FY, 2017)
Cost of goods
$72.6m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$219.6m (FY, 2017)
Gross profit
CHF1.8b (FY, 2017)
Gross profit
$308.1m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
$102.5m (FY, 2017)
Net income
CHF728m (FY, 2017)
Net income
($102.5m) (FY, 2017)
Net income
N/A
Net income
($70.2m) (FY, 2016)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 875m
Total funding raised
$ 27.1m
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Lonza
HQ
Basel, CH
Employees
14,618

Lonza supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries.

View company
Assertio Therapeutics
HQ
Newark, US
Employees
434↓ 11% decrease

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.

View company
Aradigm
HQ
Hayward, US
Employees
23

Aradigm is a pharmaceutical company focused on the development of drugs for the treatment of severe respiratory diseases.

View company
Albany Molecular Research
HQ
Albany, US

Albany Molecular Research is a pharmaceutical services organization offering Discovery/Development solutions, and Drug Product and API Manufacturing.

View company